Morgan Stanley Downgrades ResMed to Equal-Weight, Lowers Price Target to $230
Benzinga Newsdesk 4 months ago
NewsDowngradesPrice TargetAnalyst Ratings
Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight and lowers the price target from $286 to $230.
Morgan Stanley analyst David Bailey downgrades ResMed (NYSE:RMD) from Overweight to Equal-Weight and lowers the price target from $286 to $230.